Cas:5256-79-1 Octaphenylsilsesquioxane manufacturer & supplier

Chemical Name:Octaphenylsilsesquioxane

CAS.NO:5256-79-1

Synonyms:Octaphenylsilsesquioxane;Hydrogen-POSS;octaphenyl-silsesquioxane;1,3,5,7,9,11,13,15-Octaphenylpentacyclo[9.5.1.1.1.1]octasiloxane;1,3,5,7,9,11,13,15-OCTAPHENYLPENTACYCLO-OCTASILOXANE;Pentacyclo[9.5.1.1.1.1]octasiloxane, 1,3,5,7,9,11,13,15-octaphenyl-;octaphenylpentacyclosilsesquioxane;pss-octaphenyl substituted;octaphenyloctasilsesquioxane;Poly(Phenyl Silsesquioxane);Perphenyloctasilsesquioxane;phenyl8Si8O12;Phenyl-POSS;Nitrophenyl-POSS;1,3,5,7,9,11,13,15-Octaphenylpentacyclo[9.5.1.13,9.15,15.17,13]octasiloxane;MFCD00308870;OCTAPHENYL-T8-SILSESQUIOXANE;Aminophenyl-POSS

Molecular Formula:C₄₈H₄₀O₁₂Si₈

Molecular Weight:1033.508

HS Code:

Physical and Chemical Properties:

Melting point:>350ºC

Boiling point:41.5ºC at 760mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.659

PSA:110.76000

Exact Mass:1032.067383

LogP:3.02240

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Octaphenylsilsesquioxane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Aminophenyl-POSS physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Aminophenyl-POSS Use and application,1,3,5,7,9,11,13,15-Octaphenylpentacyclo[9.5.1.1.1.1]octasiloxane technical grade,usp/ep/jp grade.

Related News: Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress. Octaphenylsilsesquioxane manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. Octaphenylsilsesquioxane supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. Octaphenylsilsesquioxane vendor Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.�� Octaphenylsilsesquioxane factory The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.